Nabla Bio

George Church-lab spin-out whose JAM platform designs antibodies computationally — backed by $550M+ and $1B pharma partnerships.

1. Core Product / Service

Nabla Bio (Massachusetts; Boston vs. Cambridge is inconsistent across sources [2][4]) builds JAM ("Joint Atomic Model"), a multimodal generative AI platform that designs antibodies from scratch. JAM models the target's amino-acid sequence and/or structure and "autocompletes" the antibody that will bind it; the newer JAM-2 jointly models the antibody sequence, the target's atomic structure, and their interaction [1]. A defining capability is "introspection" — test-time scaling via best-of-N rejection sampling, where the model generates candidate batches, keeps the best, and seeds the next round, so compute buys quality [1].

Nabla claims first-in-class computationally designed binders to hard targets including the GPCR CXCR7 (ACKR3) and Claudin-4, plus the first computationally designed antibody GPCR agonists [1].

No disclosed proprietary clinical asset: the business runs on partner programs (upfront + milestones + royalties). A September 2026 article reports the company expects first-in-human trials of its AI-designed antibodies within roughly one to two years; this is single-source and no specific asset has been named [2][4].

2. Target Users & Pain Points

• Pharma partners (AstraZeneca, Bristol Myers Squibb, Takeda) who want de novo antibodies and multispecifics against difficult targets.
• Pain solved: hard-to-drug targets (GPCRs, ion channels) resist traditional discovery; Nabla's design-first approach opens them to biologic intervention, and its in-house wet lab (reported ~100,000 antibodies characterized in ~3 weeks) closes the design→validation loop — 3–4 weeks by the company's own account [1][2].

3. Competitive Landscape

4. Unique Observations

• Partnership-funded, capital-light: with only ~$37M raised but >$550M and then >$1B in pharma deal value, Nabla is the sector's clearest example of funding a platform through milestone-heavy biobucks rather than VC equity — low dilution, high dependency on partner programs advancing [1].
• "Design, not discovery" thesis: Nabla's founding bet — that next-gen antibodies will be designed by AI rather than discovered by screening natural repertoires — is a direct articulation of the shift tracked in ai-for-science [1].
• JAM-2 as a named reference model: an antibody-design company survey flagged JAM-2 alongside Absci and Chai, suggesting it is now a canonical reference point for AI antibody design [local].

5. Financials / Funding

• Seed: $11M (Dec 2021; co-led Khosla Ventures + Zetta Venture Partners) [1].
• Series A: $26M (May 2024; led Radical Ventures) — total confirmed VC ~$37M [1][2].
• Series B (unconfirmed): PitchBook lists a $70M Series B dated May 2026 [3]; no company announcement or press coverage was found. (Note: an unrelated clinical-documentation company also named Nabla has raised a $70M round — a possible source of confusion.)
• Partnerships: first Takeda collaboration (2022) [2]; AstraZeneca + BMS + Takeda (May 2024, >$550M aggregate potential upfront+milestones plus royalties); second Takeda collaboration (Oct 2025, upfront and research payments in the "double-digit millions", >$1B potential milestones) [1][2].

6. People & Relationships

• Co-founders: Surge Biswas (CEO; from George Church's lab), Frances Anastassacos (Harvard PhD, former VC); academic co-founder George Church (Harvard/Wyss). The company is a Y Combinator alumnus [2].
• Partners: AstraZeneca, Bristol Myers Squibb, Takeda.
• Peers: absci, chai-discovery, isomorphic-labs, insilico-medicine.

Sources

• [1] BioPharmaTrend, "Takeda Expands AI-Driven Antibody Design Partnership with Nabla Bio in a Billion-Dollar Deal" (2026-08-24); AI Wiki — Nabla Bio profile (2026-08-24)
• [2] Internal research notes — AI-bio wet-lab and business-model verification, Oct 2026 (compiles Business Wire release on the second Takeda collaboration and Series A coverage)
• [3] PitchBook — Nabla Bio profile (2026-10-14; single aggregator source)
• [4] Crypto Briefing, "Nabla Bio AI antibody human trials" (Sep 2026; accessed 2026-10-14)